Verdict Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Triple combo: calming Alzheimer’s agitation with AI, wearables and a novel drug

BioXcel Therapeutics is developing an acute agitation drug, BXCL501, for Alzheimer’s disease. To improve management and prevention of agitation, the company is leveraging an existing wearable device and developing AI algorithms to predict and prevent aggressive agitation. Allie Nawrat explores this novel, triple combination initiative to prevent and treat symptoms of Alzheimer’s.

Close
Close
Close

Driving towards the implementation of the new Medical Devices Regulations (MDR)

  On 5 April 2017, two new Medical Devices Regulations (MDR) on medical devices were adopted, and they entered into…
Read More…

Close

Go Top